RxDoctor Payments Data

Jennifer Pernesky

Family · Roanoke Rapids, NCNPI 1588257935

Payments from drug & device makers

$473in general payments, 2019–2025

Across 28 payments — averaging $16.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$108
  • Dexcom, Inc.$50
  • Amgen$48
  • Boehringer Ingelheim$45
  • Organon$38
  • Lilly USA, LLC$31
  • plus $154 from 7 others

What the payments were for

  • Food & beverage$473100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$473 in reported general payments places this provider in the 55th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$676
Medicare patients
34
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$71,918
FarxigaDapagliflozin Propanediol41$36,661
EliquisApixaban26$25,146
JardianceEmpagliflozin21$23,906
JanuviaSitagliptin Phosphate22$20,902
InvokanaCanagliflozin30$16,785
EntrestoSacubitril/Valsartan15$15,439
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$12,908
XareltoRivaroxaban11$10,438
LinzessLinaclotide12$9,877
SymbicortBudesonide/Formoterol Fumarate29$6,760
Insulin Lispro Protamine MixInsulin Lispro Protamin/Lispro11$5,668
Victoza 2-PakLiraglutide11$5,623
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl25$5,456
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$3,984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$108$71,91861 claims
AstraZenecaFarxiga, Symbicort$13$43,42270 claims
Boehringer IngelheimJardiance$45$23,90621 claims
GSKTrelegy Ellipta$29$12,90814 claims
AbbVieLinzess$17$9,87712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,522 family providers in North Carolina.

Other family in Roanoke Rapids

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →